NCT07637734Phase 3Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Study sponsor: Verrica Pharmaceuticals Inc. · VRCA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-05Estimated

Enrollment · participants300Estimated

Source updated2026-09-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-03 · 2 fields changed

Primary completion date changed

− Before

~~Aug 2027~~

+ After

May 2027

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Proportion of subjects achieving complete clearance of all treatable common warts (baseline and new) at the Day 84 (EOT) Visit.; description: To evaluate the efficacy of YCANTH (VP-102/TO-208) relative to Vehicle by assessing the proportion of subjects achieving complete clearance defined by complete resolution of all common warts as assessed visually by a Blinded Assessor of all treatable common warts, at the EOT Visit (Day 84).; timeFrame: Day 84 (0/+8 days)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history